z-logo
open-access-imgOpen Access
Helicobacter pyloriInfection in Nonsteroidal Anti-inflammatory Drug Users
Author(s) -
Yun Jeong Lim,
Su Jin Hong
Publication year - 2014
Publication title -
korean journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.203
H-Index - 25
eISSN - 2233-6869
pISSN - 1598-9992
DOI - 10.4166/kjg.2014.64.2.70
Subject(s) - medicine , nonsteroidal , helicobacter pylori , helicobacter pylori infection , drug , anti inflammatory , helicobacter infections , gastroenterology , pharmacology
NSAID-induced upper gastrointestinal (GI) damage occurs easily in people with a prior history of complicated or uncomplicated ulcers. Many recent clinical studies have proved the benefit of Helicobacter pylori eradication in NSAID users; however, the exact pathophysiologic relationship between concomitant H. pylori infection and NSAID use has not yet been fully elucidated. Testing and eradication of H. pylori are generally recommended in patients who are at a high risk for NSAID-induced GI damage. However, in high-risk patients, ulcer prophylaxis with proton pump inhibitor or misoprostol is needed even if H. pylori has been successfully eradicated. In low-risk patients, it is still questionable whether or not eradication of H. pylori can reduce upper GI damage. However, in western countries, due to its cost effectiveness, testing and eradication of H. pylori is recommended before starting aspirin or NSAID irrespective of the risk level. In regions with a high prevalence of H. pylori infection (>20%), the usefulness of testing and eradication of H. pylori has not yet been determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom